понедельник, 13 марта 2017 г.

Mylan Settles With Genentech Over Patents for Breast Cancer Drug

Mylan Settles With Genentech Over Patents for Breast Cancer Drug


Pharmaceutical company Mylan said Monday it has settled with Genentech Inc. and F. Hoffmann-La Roche over patents for Herceptin, its brand name for trastuzumab, a treatment for certain HER2-positive breast cancers. The settlement provides Mylan with global licenses for its trastuzumab product.



from Biotech News